Alzheimer’s disease

View All

Dementia
Antihypertensive drugs decrease Dementia rate

Dementia is an umbrella term, usually of a chronic or progressive nature, causing deterioration in cognitive function. Associated with memory loss and decline other in other thinking skills, it is just not restricted to that. Problems with language, decision making, judgement, abstract thinking, struggling in takin...

Find More

the business cocktail lemborexant
The Business Cocktail

EISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out  Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multip...

Find More

Alzheimer’s drug fails! Is it time to move on?

Alzheimer’s is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum.  But for more than two decades now Scientists from everywhere have been working on the “amyloid hypothesis". It has been a long-standing theory that brains of the people affected ...

Find More

EPILEPSY- A Neurological Disorder

What is Epilepsy? Epilepsy is a neurological disorder which mainly affects the central nervous system. It is a chronic and non-communicable disorder associated with unpredictable seizures which affect the body and can result in injuries hence is a physical condition too. Anyone can develop Epilepsy at any a...

Find More

Gilead
Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal

Tetra, Shionogi sign USD 40 Million deal for Alzheimer’s disease and fragile X syndrome Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer’s disease and fragile X syndrome. Shionogi will give a USD 5 million upfront payment and USD 35 million in equ...

Find More

HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing

HER2 Vaccine Candidate Meet Phase 1b Study An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, successfully finished its phase 1b clinical trial and head to a phase 2 study. The first tranche of data from the 14-patient trial comes...

Find More

alzheimer's
Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M

Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclin...

Find More

dementia
Does coconut oil help prevent dementia?

Coconut oil and dementia  Presently, we have a lack of evidence in displaying coconut oil playing any role in treating dementia or its symptoms. Albeit, there have been some claims regarding coconut oil that it could be used as a treatment, or even a cure, for Alzheimer's disease. But, currently, there is not e...

Find More

COMMERCIAL AND OTHERS

Cytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles  CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufactur...

Find More

KEY CLINICAL OUTCOMES

Streamlined solutions provided by Cognitive Clinical Trials (CCT) related to the treatment and prevention of Alzheimer’s disease Congnitive Clinical Trials (CCT) has introduced a new research model that prevail over the top obstacles being faced by the researchers related to the treatment and prevention of Alzheime...

Find More